NEW YORK, Aug. 13 - Applied Biosystems and Myriad Proteomics today said they will collaborate to develop new proteomics technology.
The deal will employ the companies' existing capabilities, such as ABI's mass spectrometry and Myriad's experience with protein-protein interactions, to devise more effective ways of analyzing proteins and map the human proteome.
In the process ABI will have its 4700 protein analyzer put through its paces in hopes of tweaking its performance in protein-protein-interaction studies, said Stephen Martin, director of ABI's protein research center.
Participating in the collaboration will be scientists from ABI's Framingham, Wash., facility, and Myriad Proteomics' new space in Salt Lake City, the companies said. Myriad Proteomics was founded by Myriad Genetics, Oracle, Hitachi, and Friedli Corporate Finance.
Click here for more information.